The invention is directed to a method for treating a cyclooxygenase-2 mediated disease or condition in a mammalian patient at risk of a thrombotic cardiovascular event, wherein the patient is on aspirin therapy to reduce the risk of the thrombotic cardiovascular event,
comprising orally concomitantly or sequentially administering to the patient a cyclooxygenase-2 selective inhibitor in an amount effective to treat the cyclooxygenase-2 mediate disease or condition, and
a nitric oxide donating compound in accordance with Formula I
or a pharmaceutically acceptable salt thereof, wherein the nitric oxide donating compound is administered in an amount effective to reduce the gastrointestinal toxicity caused by the combination of the cyclooxygenase-2 selective inhibitor and aspirin. Pharmaceutical compositions are also encompassed.
本发明涉及一种治疗哺乳动物患有环氧合酶-2介导的疾病或病状的方法,该患者有心血管血栓事件的风险,并正在接受
阿司匹林治疗以减少心血管血栓事件的风险,包括同时或顺序口服给予患者一种环氧合酶-2选择性
抑制剂,其剂量足以治疗环氧合酶-2介导的疾病或病状,以及一种符合公式I或其药学上可接受的盐的
一氧化氮供体,其中该
一氧化氮供体的剂量足以减少环氧合酶-2选择性
抑制剂和
阿司匹林联合使用引起的胃肠道毒性。还包括制药组合物。